Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Who Have Not Received Prior Treatment

Inclusion Criteria: * Type 2 Diabetes Mellitus of less than 5 years in duration * Have never received hypoglycemic therapy * Aged 18 to 65 years * Fasting blood glucose between 130 and 220 mg/dL (7.2 to 12.2 mmol/L) for Cohorts A-D and between 140 and 220 mg/dL (7.8 to 12.2 mmol/L) for Cohort E * HbA1c between 6.8 and 10.0% for Cohorts A-D and between 7.5 and 11.0% for Cohort E * Body Mass index \> 25 and \< 35 kg m -2 Exclusion Criteria: * Medication that may affect glucose homeostasis (e.g. systemic glucocorticoid) within one month of screening * Clinically significant abnormalities in medical history or physical exam * Clinically significant abnormalities on laboratory examination * History of HIV infection * Active infection requiring antiviral or antimicrobial therapy * Malignancy (with the exception of basal or squamous cell carcinoma of the skin if adequately treated and no recurrence for \> one year at the time of screening) * Any other concurrent condition which, in the opinion of the Investigator, would preclude participation in or interfere with compliance * Alcohol or drug abuse * Undergoing or have undergone treatment with another investigational drug, biologic agent or device within 90 days of screening * Abnormal serum creatinine concentration defined as \> 1.5 mg/dL (132.6 micro mol/L) for males and \> 1.2 mg/dL (106 micro mol/L) for females * Medications that may affect coagulation (heparin, warfarin, etc.) with the exception of acetylsalicylic acid or non-steroidal anti-inflammatory agents. * Allergy to sulfur-containing medications